Antares Pharma Posts Narrower Loss In Q4 - Quick Facts

(RTTNews) - Antares Pharma, Inc. (ATRS) reported a fourth-quarter net loss of $4.5 million compared to a loss of $6.6 million for the same period in 2015. Net loss per share was $0.03 compared to a loss of $0.04. On average, three analysts polled by Thomson Reuters expected the company to report a loss per share of $0.04, for the quarter. Analysts' estimates typically exclude special items.

Fourth-quarter revenue was $14.2 million compared to $11.8 million, prior year. Analysts expected revenue of $11.25 million, for the quarter. Product sales were $9.7 million compared to $9.0 million, prior year. The company said the increase in product sales was primarily driven by an increase in auto and pen injector sales associated with the launch of sumatriptan injection and continued growth of OTREXUP.

Robert Apple, CEO, said: "We look forward to 2017 and beyond as we anticipate the potential for a number of internal and partnered combination drug-device product approvals over the coming years."